Anti-tumor necrosis factor-α therapy may not be safe during pregnancy in women with inflammatory bowel disease: an updated meta-analysis and systematic review

被引:2
|
作者
Huang, Wei [1 ]
Zhang, Xinxing [1 ]
Zhang, Li [1 ]
Dai, Xiaosong [1 ]
Chen, Heping [1 ]
Xie, Qin [1 ]
机构
[1] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Dept Geriatr Med & Gastroenterol, Chengdu, Peoples R China
基金
中国国家自然科学基金;
关键词
Inflammatory bowel disease; Tumor necrosis factor; Pregnancy; Biologic treatment; Adverse pregnancy outcomes; TNF-ALPHA; EPIDEMIOLOGY; MULTICENTER; CONSENSUS; OUTCOMES;
D O I
10.1186/s12884-024-06443-w
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background Inflammatory Bowel Disease (IBD) affects reproductive-aged women. Active disease can lead to decreased fertility. Although the vast majority of international guidelines recommend for the continuation of anti-TNF-alpha during pregnancy, recent studies have raised concerns about the safety of anti-tumor necrosis factor-alpha (TNF-alpha) therapy during pregnancy, both for patients and for physicians.Methods Studies that evaluate the safety of anti-TNF-alpha therapy in pregnant women with IBD were identified using bibliographical searches. An updated meta-analysis was performed for pregnancy outcomes, such as live birth, abortion, still birth, preterm birth, low birth weight, congenital abnormalities, and neonatal infection. Odds ratio (OR) with 95% confidence interval (CI) are reported. Data on disease activity, timing of anti-TNF-alpha therapy were collected for further analysis.Results Overall, 11 studies were screened from on-line databases and international meeting abstracts. An increased risk of abortion (OR, 1.33; 95% CI, 1.02-1.74; P = 0.04) and preterm birth (OR, 1.16; 95% CI, 1.05-1.28; P = 0.004), and a decreased risk of live birth (OR, 0.83; 95% CI, 0.74-0.94; P = 0.002]) were found in the anti-TNF-alpha therapy group compared with the control group (no use of anti-TNF-alpha therapy). The subgroup analyses based on the disease activity showed there is no significant association between the use of anti-TNF-alpha therapy during pregnancy on adverse pregnancy outcomes of abortion, preterm birth, and live birth. The rates of still birth, low birth weight, and congenital abnormalities in the anti-TNF-alpha therapy group were not significantly different from those in the control group.Conclusions Anti-TNF-alpha therapy does not increase the risks of still birth, low birth weight, and congenital abnormalities; however it may be assicated with increased risks of abortion and preterm birth, which are accompanied by a lower rate of live birth. Although these findings may be confounding by potential disease activity, they offer some opposite viewpoints with biologic agent use. Therefore, more studies are required to further confirm the safety of anti-TNF-alpha therapy in pregnancy with IBD.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] The incidence, clinical characteristics and serological characteristics of anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: A systematic review and meta-analysis
    Dai, Cong
    Wang, Yi-nuo
    Tian, Wen-ning
    Huang, Yu-Hong
    Jiang, Min
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 112
  • [22] Systematic review and meta-analysis: risks of postoperative complications with preoperative use of anti-tumor necrosis factor-alpha biologics in inflammatory bowel disease patients
    Moosvi, Zain
    Duong, Jacqueline
    Bechtold, Matthew L.
    Nguyen, Douglas L.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (06) : 799 - 816
  • [23] Corticosteroids and Thiopurines, But Not Tumor Necrosis Factor Antagonists, are Associated With Cytomegalovirus Reactivation in Inflammatory Bowel Disease A Systematic Review and Meta-Analysis
    Shukla, Tushar
    Singh, Siddharth
    Tandon, Parul
    McCurdy, Jeffrey D.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2017, 51 (05) : 394 - 401
  • [24] The risk of venous thromboembolism in women with inflammatory bowel disease during pregnancy and the postpartum period A systematic review and meta-analysis
    Kim, Yeon Hee
    Pfaller, Birgit
    Marson, Alanna
    Yim, Hyeon Woo
    Huang, Vivian
    Ito, Shinya
    MEDICINE, 2019, 98 (38)
  • [25] Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window
    Papamichael, Konstantinos
    Vande Casteele, Niels
    Ferrante, Marc
    Gils, Ann
    Cheifetz, Adam S.
    INFLAMMATORY BOWEL DISEASES, 2017, 23 (09) : 1510 - 1515
  • [26] Anti-tumor Necrosis Factor Agents and Tuberculosis in Inflammatory Bowel Disease
    Yunho, Jung
    KOREAN JOURNAL OF GASTROENTEROLOGY, 2020, 75 (01): : 1 - 3
  • [27] Anti-Tumour Necrosis Factor α Therapies and Inflammatory Bowel Disease Pregnancy Outcomes: A Meta-analysis
    Shihab, Zaid
    Yeomans, Neville D.
    De Cruz, Peter
    JOURNAL OF CROHNS & COLITIS, 2016, 10 (08): : 979 - 988
  • [28] Arterial Stiffness in Inflammatory Bowel Disease: An Updated Systematic Review and Meta-Analysis
    Lu, Qiongqiong
    Shi, Rui
    Mao, Tangyou
    Wang, Zhibin
    Sun, Zhongmei
    Tan, Xiang
    Wang, Yi
    Li, Junxiang
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2021, 32 (05): : 422 - +
  • [29] Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with antitumour necrosis factor therapy
    Nigam, Gaurav B.
    Bhandare, Anirudh P.
    Antoniou, George A.
    Limdi, Jimmy K.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (03) : 346 - 357
  • [30] Tumor necrosis factor-α in cardiovascular biology and the potential role for anti-tumor necrosis factor-α therapy in heart disease
    Sack, MN
    PHARMACOLOGY & THERAPEUTICS, 2002, 94 (1-2) : 123 - 135